Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeeking Alpha • 09/10/25
Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 09/04/25
Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/03/25
Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)Seeking Alpha • 09/03/25
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?Zacks Investment Research • 08/25/25
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?Zacks Investment Research • 08/13/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXELGlobeNewsWire • 08/09/25
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?Zacks Investment Research • 08/05/25
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the StockZacks Investment Research • 08/04/25
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"Zacks Investment Research • 07/30/25
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong BuyZacks Investment Research • 07/29/25
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 PlansBenzinga • 07/29/25